

FISH & RICHARDSON P.C.

Exhibit C

225 Franklin Street
Boston, Massachusetts
02110-2804

Telephone
617 542-5070

Facsimile
617 542-8906

Web Site
www.fr.com

Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

VIA FACSIMILE & FIRST CLASS MAIL

January 26, 2007

Sandip H. Patel, Esq.
Marshall, Gerstein & Borun LLP
233 South Wacker Drive
6300 Sears Tower
Chicago, IL 60606-8357

Re: *Amgen, Inc. v. F. Hoffmann-La Roche Ltd. et al.*
Civil Action No. 05 CV 12237 WGY (D. Mass.)



ATLANTA

AUSTIN

BOSTON

DALLAS

DELAWARE

NEW YORK

SAN DIEGO

SILICON VALLEY

TWIN CITIES

WASHINGTON, DC

Dear Mr. Patel:

Please be advised that we represent Fresenius Medical Care North America ("FMCNA") in connection with various intellectual property matters. We understand that your client, Amgen Inc. ("Amgen"), has filed a patent infringement lawsuit against F. Hoffman-LaRoche Ltd. ("Roche") et al. in the U.S. District Court for the District of Massachusetts, Civil Action No. 05-CV-12237 ("the Lawsuit").

We understand that you sent a letter on or about January 12, 2007 (misdated as 2006), addressed to the attention of "General Counsel" of Fresenius Medical Care Holdings, Inc. ("Letter to Holdings") in connection with the Lawsuit. We also understand that you sent a form letter on or about January 12, 2007 ("Form Letter") to multiple entities affiliated with FMCNA. A sample of the Form Letter is attached hereto. We further understand that both the Letter to Holdings and the Form Letter have been the subject of discussions on January 24, 2007 between Ronald L. Castle, Esq. of FMCNA and Amgen in-house attorneys as well as between Jules Jay Morris, Esq. of FMCNA and yourself. Both the Letter to Holdings and the Form Letter have been referred to us for formal response.

Initially, we ask that any further communications that you have with FMCNA or any entity affiliated with FMCNA relating to the Lawsuit be directed to our attention.

Second, the Form Letter suggests that you view today, January 26, 2007, as the deadline for any objections to the Form Letter, and that failure to provide such objections will serve as a waiver of any objections. Please be advised that on behalf of FMCNA and any of its affiliated entities that received the Form Letter that we hereby **do object** to the proposed production of documents as set forth in the Form Letter. Accordingly, the absence of responses directly from the individual entities you contacted is immaterial and may **not** be construed as a waiver or consent to your proposal. If you did receive any response from the individual entities you contacted, please let us know and forward same for our review.

Sandip H. Patel, Esq.
January 26, 2007
Page 2

Third, we understand that over 1,000 copies of the Form Letter have been issued, and that Amgen is not certain which of the addressees are and are not affiliated with FMCNA. Accordingly, we ask that you send to us the full list of all addressees of the Form Letter.

Finally, prior to the production of any documents that are subject to either the Letter to Holdings or the Form Letter, or any other documents that contain information which is confidential or proprietary to FMCNA or any of its affiliated entities, we ask that you provide the documents to us for prior review, along with (a) an identification of which document request each document is believed to be responsive to, and (b) an identification of which claim, defense or counterclaim in the Lawsuit each document is believed to be responsive to.

Very truly yours,

A handwritten signature in black ink that reads "Mark J. Hebert / 1/26/07". The signature is written in a cursive style.

Mark J. Hebert

MJH/amc

Cc/fax: Ronald C. Castle, Esq., FMCNA
Jules Jay Morris, Esq., FMCNA
Kimberlin Morley, Esq., Amgen
Cantrell Bernau, Esq., Amgen
Scott Larsen, Esq., Amgen

MARSHALL, GERSTEIN & BORUN LLP

ATTORNEYS AT LAW

SANDIP H. PATEL, ESQ.

January 12, 2007

ATTN: Vice President of Dialysis Services Finance and Administration
National Medical Care, Incorporated
920 Winter Street
Waltham, MA 02451

Re: *Amgen Inc. v. F. Hoffman-LaRoche Ltd., et al.*
Civil Action No. 05-12237 (WGY) (D. Mass.)


Ladies and Gentlemen:

We write on behalf of Amgen Inc. ("Amgen") regarding documents that you may consider confidential and ask your permission to disclose such documents in a legal proceeding under the terms discussed herein. As you may know, Amgen currently is in litigation with F. Hoffman-LaRoche Ltd., et al ("Roche") in a patent infringement suit pending in the United States District Court for the District of Massachusetts, Civil Action No. 05-12237. Roche has served document requests on Amgen that implicate your agreement with Amgen regarding the purchase of EPOGEN[®] and ARANESP[®]. Pursuant to the standard terms of the agreement, Amgen is required to provide you with notice prior to producing the documents to Roche. We hereby provide you with such notice.

The agreement, and any associated documentation, will be produced in accordance with the terms of the enclosed Protective Order unless you provide us with notice of objection in writing by January 26, 2007. Please direct any such written notice to Kimberlin Morley at Amgen prior to this date. Please direct any questions to Ms. Morley or Cantrell Bernau at Amgen, both of whom can be reached at One Amgen Center Drive, MSC 28-2-C, Thousand Oaks, CA 91320-1799; Fax (805) 447-1010.

Thank you for your attention to this matter.

Very truly yours,



Sandip H. Patel

SHP/

Enclosure

cc: Ms. Cantrell Bernau
Ms. Kimberlin Morley